Yesterday it was Amplichip ® and today it is GeneSightRxTM tomorrow……
Chakradhara Rao U S
Friday, 23 October 2009 07:19 UTC
After the approval of Amplichip® in the year 2005, many giants and some small players in pharmaceutical industry started focussing on personalized medicine products. The outcome of such thirst is GeneSightRx ™ by AssureRx which is developed to analyze several important gene variants determining psychiatric medication using cutting edge technology (launched on 20 th October 2009). Right now the test is available at AssureRx laboratory, which gives online reporting to the healthcare professional after the analysis. Even though exact details of the genetic variants included in the test are not revealed (May be I did not search for it) mostly includes variants in the genes coding for drug metabolizing enzymes (CYPs)involved in the metabolism and some of the targets of psychiatric medication.
For more details regarding the product you may visit the company’s website at http://www.assurerxhealth.com.
P.S. This is not a promotional act and this is just a bit of information available elsewhere on the internet.
-
Replies
-
Exciting! Have you found the marker list for GeneSighRx?
And the answer for tomorrow, probably you may want to check Affymetrix DMET plus microarray. Again this is not an ad, for interest only.
-
I could not check for the markers list, that may include probably only few metabolizing enzyme gene variants and drug target gene variants (my guess). Whereas The DMET™ Plus Assay is a comprehensive drug metabolism microarray capable of simultaneously genotyping ~2,000 common and complex functional variants in 225 drug-metabolizing enzymes, transcription regulators, and transporter genes. So obviously this gives more information than the previous one. But sometimes more information may leads to more confusion. So specific information is always better than the entire information. But it is for sure that The DMET Plus Array and analysis tools facilitate highly multiplexed genotyping of functional variants across full pharmacokinetic pathways.
(The information given above obtained from Affymetrix, Inc., 3420 Central Expressway, Santa Clara, CA 95051)
-
